Bottom line
How much do FTXH and DLHIX overlap?
44% of their top holdings overlap by weight. 13 securities appear in both funds' top 25, making up 46.9% of FTXH's assets and 37.5% of DLHIX's. They share a meaningful core but differ in the rest of the portfolio.
DLHIX holds far more positions (108 vs 51), so it is broader beyond the top names.
Updated Nov 22, 2026
Overlap at a glance
Holdings FTXH and DLHIX have in common
| Holding | % of FTXH | % of DLHIX | Overlap |
|---|---|---|---|
| Eli Lilly & Company LLY | 7.77% | 4.16% | 4.16% |
| Abbvie Inc ABBV | 7.39% | 4.19% | 4.19% |
| Merck & Company Inc MRK | 7.07% | 3.68% | 3.68% |
| Viatris Inc VTRS | 3.62% | 2.48% | 2.48% |
| Vertex Pharmaceuticals Inc VRTX | 3.41% | 1.66% | 1.66% |
| Amgen Inc AMGN | 3.18% | 2.27% | 2.27% |
| Pfizer Inc PFE | 2.97% | 3.84% | 2.97% |
| Gilead Sciences Inc GILD | 2.89% | 3.54% | 2.89% |
| Regeneron Pharmaceuticals Inc REGN | 2.72% | 3.91% | 2.72% |
| Illumina Inc ILMN | 1.98% | 2.11% | 1.98% |
| Neurocrine Biosciences Inc NBIX | 1.37% | 1.57% | 1.37% |
| Alkermes Plc ALKS | 1.35% | 1.82% | 1.35% |
| Halozyme Therapeutics Inc HALO | 1.21% | 2.30% | 1.21% |
Source: SEC Form N-PORT (periods Jun 30, 2026 / Jun 30, 2026)
Free weekly newsletter
The Fund Letter
Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.
Free. Unsubscribe anytime. We never sell your email.
What each fund holds that the other doesn't
Top-25 holdings that appear in only one of the two funds' top 25.
Only in FTXH
- Johnson & Johnson — 6.96%
- Bristol-myers Squibb Company — 6.29%
- Biogen Inc — 3.84%
- Cardinal Health Inc — 3.53%
- United Therapeutics Corp — 2.72%
- Jazz Pharmaceuticals Plc — 2.49%
- Incyte Corp — 2.39%
- Zoetis Inc — 1.87%
- Exelixis Inc — 1.72%
- Charles River Laboratories International Inc — 1.49%
- Medpace Holdings Inc — 1.41%
- Ptc Therapeutics Inc — 1.37%
Only in DLHIX
- Ucb Sa — 5.19%
- Unitedhealth Group Inc — 3.88%
- Astrazeneca Plc — 3.27%
- Elevance Health Inc — 3.25%
- Roche Holding Ag — 3.01%
- Chugai Pharmaceutical Co Ltd — 2.77%
- Oruka Therapeutics Inc — 2.41%
- Viking Therapeutics Inc — 1.72%
- Roivant Sciences Ltd — 1.60%
- Arcus Biosciences Inc — 1.56%
- Zimmer Biomet Holdings Inc — 1.42%
- Boston Scientific Corp — 1.42%
Asset mix
| Asset type | FTXH | DLHIX |
|---|---|---|
| Stocks | 99.9% | 94.8% |
| Preferred stock | — | 3.0% |
| Cash & short-term funds | 0.1% | 2.0% |
Source: SEC Form N-PORT (periods Jun 30, 2026 / Jun 30, 2026)
Country mix
| Country | FTXH | DLHIX |
|---|---|---|
| US | 95.6% | 75.4% |
| BE | — | 5.2% |
| IE | 3.8% | 3.2% |
| GB | — | 3.3% |
| CH | — | 3.0% |
| JP | — | 2.8% |
| FR | — | 2.0% |
| NL | — | 1.6% |
Source: SEC Form N-PORT (periods Jun 30, 2026 / Jun 30, 2026)
Check another pair
FAQ
How much do FTXH and DLHIX overlap?
What stocks do FTXH and DLHIX have in common?
Should I own both FTXH and DLHIX?
Which holds more stocks, FTXH or DLHIX?
Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.